• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    [Rinsho ketsueki] The Japanese journal of clinical hematology

    [Rinsho ketsueki] The Japanese journal of clinical hematology

    JournalISSN 0485-1439eISSN 1882-0824

    年发文量

    研究主题

    论文(9896)

    排序
    1[Aplastic Anemia Developed after Treatment with Durvalumab].
    Kaho Maeshima, Yo Sakayori,Hiroki Yokoyama,Atsushi Katsube,Kazuhito Suzuki,Hiroto Ishii,Susumu Tanoue,Hideki Uryu,Daiki Hattori, Yasutaka Mochizuki,Shingo Yano

    A 76-year-old woman with stage IIIB squamous cell lung carcinoma developed pancytopenia following maintenance therapy with durvalumab. She was diagnosed with squamous cell lung carcinoma (T4N2M0, stageIIIB) in December 2023. Following a favorable response to chemoradiotherapy, maintenance therapy with durvalumab was initiated in June 2024. Thrombocytopenia was observed starting in August, and platelet count had decreased to 22,000/µl in October, leading to the discontinuation of durvalumab. However, the condition progressed to pancytopenia. Bone marrow biopsy revealed hypocellular marrow without dysplasia, fibrosis, or hemophagocytosis. Additional findings included paroxysmal nocturnal hemoglobinuria-type blood cells and fatty marrow replacement on spinal MRI. Based on these comprehensive findings, the patient was diagnosed with aplastic anemia (AA) in January 2025. Immunosuppressive therapy combining antithymocyte globulin, cyclosporine A, and eltrombopag was initiated in February 2025, resulting in a favorable response. AA is a relatively rare immune-related adverse event, and reports of AA induced by durvalumab are extremely limited. This case highlights the importance of considering AA in the differential diagnosis of persistent thrombocytopenia or pancytopenia during immune checkpoint inhibitor therapy.

    2026
    引用
    AI阅读
    加入学术空间
    2[Intrathecal Immunoglobulin Administration for Refractory Viral Central Nervous System Infection after Allogeneic Hematopoietic Stem Cell Transplantation].
    Masaaki Matsuo,Shinsuke Kusakabe, Ryumei Kurashige, Kentaro Fukushima,Keiichi Nakata,Akihisa Hino,Hidenori Kasahara, Tomoaki Ueda, Jiro Fujita,Naoki Hosen

    Central nervous system (CNS) viral infections after allogeneic hematopoietic stem cell transplantation are associated with poor prognosis and have limited therapeutic options. We report three cases of refractory CNS viral infection treated by combination therapy with antiviral agents and intrathecal immunoglobulin administration. Case 1 involved cytomegalovirus encephalitis, Case 2 varicella zoster virus meningitis, and Case 3 human herpesvirus 6 encephalitis; all were resistant to antiviral agents. Two patients achieved viral DNA negativity in cerebrospinal fluid, and none experienced adverse events related to intrathecal injection. Although no intrathecal immunoglobulin products have been approved for use in Japan, our findings suggest that this treatment may be a viable option in selected refractory cases. Further studies are warranted to clarify the optimal agent, dosage, and schedule.

    2026
    引用
    AI阅读
    加入学术空间
    3[Hematological Diseases Caused by Excessive Complement Activation].
    Norimitsu Inoue

    The complement system, which plays a key role in innate immunity, facilitates the elimination of foreign and endogenous substances in the body. Consequently, while a balance between complement activation and regulation is typically maintained, a disruption of this balance can lead to various diseases. Paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome (aHUS) are diseases in which abnormal complement regulatory factors cause excessive complement activation. To accurately diagnose diseases such as aHUS, international standard complement tests including activation markers such as Ba and sC5b-9 are used. The Japanese Society for Complement Research has contributed to the standardization of the International Complement Society and has established this testing system in Japan. In the present study, we revealed that the Ba level serves as a good predictive marker for the onset of thrombotic microangiopathy, a complication that typically occurs following hematopoietic stem cell transplantation. We also showed that complement activation levels rise more frequently postpartum than during pregnancy. Considering the growing number of drugs targeting the complement pathway, it is speculated that these complement markers will become available for testing in clinical settings in Japan.

    2026
    引用
    AI阅读
    加入学术空间
    4[Prophylactic or Pre-Emptive Therapy with Azacitidine or FLT3 Inhibitor after Allogeneic Hematopoietic Stem Cell Transplantation for AML and MDS].
    Yuho Najima

    Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established curative treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Advances in supportive care, infection control, and graft-versus-host disease management have substantially reduced non-relapse mortality, leading to improved transplant outcomes. However, post-transplant relapse remains the leading cause of treatment failure, particularly in patients with adverse genetic abnormalities or active disease at transplantation. Post-transplant maintenance therapy has emerged as a strategy to prevent relapse by providing a "third anti-leukemic effect" that complements the cytotoxic effect of conditioning regimens and the graft-versus-leukemia immune response. Maintenance approaches can be broadly categorized into prophylactic therapy administered during molecular remission and preemptive therapy initiated upon detection of measurable residual disease (MRD). This review summarizes the current concepts of post-transplant maintenance therapy in AML/MDS, with a particular focus on hypomethylating agents such as azacitidine and FLT3 inhibitors. It also discusses emerging evidence supporting MRD-guided treatment strategies and molecularly targeted maintenance approaches, highlighting future perspectives for optimizing relapse prevention after allo-HSCT.

    2026
    引用
    AI阅读
    加入学术空间
    5[Comparison of Clinical Characteristics and Cytogenetic Abnormalities Between Myelodysplastic Syndromes in Nagasaki Atomic Bomb Survivors and Therapy-Related Myelodysplastic Syndromes].
    Makiko Horai,Takafumi Furumoto, Eo Toriyama,Yuichi Yamada,Miki Hashimoto,Hikaru Sakamoto,Takeharu Kato,Masataka Taguchi,Shinya Sato,Koji Ando,Tomoko Hata,Yasushi Miyazaki

    BACKGROUND:Myelodysplastic syndromes (MDS) are classified into de novo and secondary forms. MDS among atomic bomb survivors (A-bomb-related MDS) is considered radiation-associated secondary MDS, whereas therapy-related MDS (t-MDS) develops after cytotoxic therapy and generally has a poor prognosis. However, differences between these two secondary MDS entities remain unclear. METHODS:We analyzed patients registered in the Nagasaki MDS cohort who were diagnosed between January 1985 and December 2023. Sixty A-bomb-related MDS and 150 t-MDS cases were included. Clinical characteristics, IPSS-R risk categories, overall survival (OS), and cytogenetic abnormalities at diagnosis were compared. RESULTS:The distribution of IPSS-R risk and cytogenetic risk categories did not differ significantly between groups. Nevertheless, median OS was significantly longer in A-bomb-related MDS than in t-MDS (65 vs. 19 months). Cytogenetic profiling revealed different features between groups, including a significantly higher frequency of monosomy 7 in t-MDS and of balanced structural abnormalities in A-bomb-related MDS. Balanced structural abnormalities were not clearly associated with prognosis. CONCLUSIONS:Although both A-bomb-related MDS and t-MDS are both classified as secondary MDS, they showed distinct prognostic and cytogenetic features. These findings suggest that the two conditions represent clinically distinct entities with different pathophysiology.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 9896 篇论文

    高被引作者

    作者引用发文
    Hiroyoshi Nishikawa20886
    Kazuma Ohyashiki155753
    Keiyo Takubo15115
    Kensei Tobinai145722
    Hiromitsu (Hiro) Nakauchi14306
    Mitsuhiro Omine140641
    Satoshi Yamazaki14064
    Seishi Ogawa139827
    Shinichiro Okamoto133546
    Shigeru Chiba129736

    高产作者

    作者引用发文
    Chihiro Shimazaki128463
    Akio Urabe123953
    Kazuma Ohyashiki155753
    Hisashi Sakamaki99352
    Yoshiro Niitsu119251
    Michito Ichimaru107249
    H Mizoguchi116348
    Shinichiro Okamoto133546
    Takahisa Yamane93545
    Hiroshi Handa43344

    相关期刊

    Acta haematologica Polonica
    Cytometry Part B:Clinical Cytometry
    Journal of Hematopathology
    International journal of hematologic oncology
    Blood research
    Leukemia research reports
    Journal of hematology
    Turkish Journal of Hematology
    Turkish journal of haematology : official journal of Turkish Society of Haematology
    Hematology/Oncology and Stem Cell Therapy